Probiotics plus standard care for mild to moderate UC
Part of Digestive system clinical trials.
This trial tests whether adding a multi-strain probiotic supplement to your usual care can help manage mild to moderate ulcerative colitis (UC). It lasts 12 weeks and requires you to stay on your current medications without changes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with ulcerative colitis (UC) confirmed by a colonoscopy and biopsy.
- Your UC currently affects at least the last part of your colon (rectosigmoid area).
- Your disease activity is mild to moderate (not severe).
- You have been on the same dose of your UC medications for at least 4 weeks and can stay on that dose for 12 weeks.
- You have not taken antibiotics in the last 2 weeks.
- You have not taken any probiotics (like supplements or probiotic foods) in the last 2 weeks.
- You can avoid taking NSAIDs (like ibuprofen, naproxen, or aspirin) for 1 week before and during the 12-week study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a specific probiotic (a type of beneficial bacteria) to see if it can help people with mild to moderate ulcerative colitis by improving the balance of gut microbes. It may be an option if you have not used many advanced treatments before.
This trial tests whether a prebiotic supplement can improve symptoms of ulcerative colitis. It may be a good option for people with active symptoms who are already on stable medications.
This trial tests a new treatment for people with ulcerative colitis (UC) whose disease is active despite taking only mesalamine or sulfasalazine. It aims to find a therapy that can reduce inflammation and improve symptoms.
This trial studies whether an oral treatment called MS-20 can improve ulcerative colitis (UC) in adults with moderate to severe disease. You may be asked to provide stool samples from home and avoid certain foods and medicines before screening and during the study.
This trial tests whether “treat-to-target” care—guided by regular symptom checks, telemonitoring, and patient education—works better than standard follow-up when starting adalimumab for ulcerative colitis. It aims to help control inflammation more effectively and reduce flare-ups.
This trial tests whether adding a probiotic supplement and trace elements to your current treatment helps manage mild to moderate ulcerative colitis. It aims to see if these additions can improve symptoms and quality of life.
Hear when a new Ulcerative Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.